VRNOVerano Holdings Corp.
VRNO
Verano Holdings Corp.1,276
Mkt Cap
$2.17BVolume
204,083.0052W High
$1.9552W Low
$0.46PE Ratio
-1.46VRNO Fundamentals
Price
$1.13Prev Close
$1.06Open
$1.0650D MA
$1.19Beta
0.81Avg. Volume
1.06MEPS (Annual)
-$0.7146P/B
0.56Rev/Employee
$216,185.26Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.
Zacks·5d ago
Verano Holdings Corp. (VRNO) Reports Q1 Loss, Tops Revenue Estimates
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +15.79% and +3.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
US Cannabis Major Reports $208M Q1 Revenue and Initiates $20M Buyback
Cannabis stocks have been in motion since April 23, when the Trump administration moved to reclassify cannabis from Schedule I to Schedule III under the DEA's controlled substances framework. As reported by CNBC, the shift does not legalize marijuana federally, but it removes longstanding research barriers, opens banking access that was previously blocked, and critically, exempts cannabis companies from IRS Code Section 280E. This exemption allows operators to deduct standard business expenses like rent and payroll for the first time, a change with direct, material implications for ...
AllPennyStocks.com·18d ago
US Cannabis Major Reports $208M Q1 Revenue and Initiates $20M Buyback
Cannabis stocks have been in motion since April 23, when the Trump administration moved to reclassify cannabis from Schedule I to Schedule III under the DEA's controlled substances framework. As reported by CNBC, the shift does not legalize marijuana federally, but it removes longstanding research barriers, opens banking access that was previously blocked, and critically, exempts cannabis companies from IRS Code Section 280E. This exemption allows operators to deduct standard business expenses like rent and payroll for the first time, a change with direct, material implications for ...
AllPennyStocks.com·18d ago
Schedule III for Some, Not All: Understanding the DOJ's Cannabis Shift
DOJ narrows cannabis reform, shifting select marijuana products to Schedule III while leaving broader federal restrictions intact.
Zacks·19d ago
Verano Holdings Corp. (VRNO) Reports Q4 Loss, Tops Revenue Estimates
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of -66.67% and +0.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Cannabis Stock VRNO Rises 40% in a Year: Time to Buy, Sell or Hold?
Verano stock has surged more than 40% in a year amid U.S. marijuana rescheduling optimism, but revenue headwinds and rising competition may keep investors cautious.
Zacks·2mo ago
Tilray Brands' Bullish Beverage Strategy: What's Behind the Optimism?
TLRY's Beverage unit faces near-term pressure, but Project 420 savings, brand resets and global expansion underpin its long-term bullish view.
Zacks·4mo ago
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
Zacks·6mo ago
<
1
2
...
>